Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesDapagliflozin: where does it fit in the treatment of type 2 diabetes
Expert Opinion in Pharmacotherapy, 10/19/09
Woo VC et al. – Dapagliflozin is a sodium–glucose co–transporter 2 inhibitor that reduces hyperglycemia by inducing significant amounts of glucosuria. Clinical trials are defining the characteristics of this new class of medication and initial results are promising.
Related Articles
Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Journal of Clinical Endocrinology and Metabolism, 11/10/09
Relevance Score: 90%
Evidence for an association with type 2 diabetes mellitus at the PPARG locus in a South Indian population
Metabolism-Clinical and Experimental, 11/03/09
Relevance Score: 90%
A Simulation of the Comparative Long-term Effectiveness of Liraglutide and Glimepiride Monotherapies in Patients with Type 2 Diabetes Mellitus
Pharmacotherapy, 10/28/09
Relevance Score: 90%
Hepatic fat and inflammation in type 2 diabetes mellitus
Metabolism-Clinical and Experimental, 10/26/09
Relevance Score: 90%
Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study
International Journal of Obesity, 10/16/09
Relevance Score: 90%
Today in Diabetes...keeping you current
Receive free subspecialty "5-minute updates" via email
The Effect of Body Mass Index on Fasting Blood Glucose and Development of Diabetes Mellitus After Initiation of Extended-Release Niacin
Metabolic Syndrome and Related Disorders, 12/08/09
Insulin Resistance and Metabolic Syndrome in the Pediatric Population
Metabolic Syndrome and Related Disorders, 12/08/09
The effect of screening on the prevalence of diagnosed type 2 diabetes in primary care
Scandinavian Journal of Primary Health Care, 12/08/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease
Pituitary, 12/08/09
Pioglitazone and mechanisms of CV protection
QJM: An International Journal of Medicine, 12/08/09
Rosiglitazone was non-inferior to metformin plus sulphonylurea for CV events but increased risk of HF and fractures in type 2 diabetes
Evidence-Based Medicine, 12/07/09
Sponsor
Article Search
Sponsor